{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T21:11:07Z","timestamp":1761340267707,"version":"build-2065373602"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,7]]},"DOI":"10.7759\/cureus.93996","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T07:22:34Z","timestamp":1759821754000},"source":"Crossref","is-referenced-by-count":1,"title":["Complete and Early Vitrectomy for Sterile Endophthalmitis After Bevacizumab: A Case Series"],"prefix":"10.7759","author":[{"given":"Agnieszka","family":"Kudasiewicz-Kardaszewska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malgorzata A","family":"Ozimek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Kardaszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Kardaszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Kapturska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Jamontt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Boninska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Slawomir","family":"Cisiecki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld PJ","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006, 355:1419-31. 10.1056\/NEJMoa054481","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.02.034","article-title":"Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE","volume":"120","author":"Brown DM","year":"2013","unstructured":"Brown DM, Nguyen QD, Marcus DM, et al.. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology. 2013, 120:2013-22. 10.1016\/j.ophtha.2013.02.034","journal-title":"Ophthalmology"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-007-0754-7","article-title":"Intraocular inflammation following intravitreal injection of bevacizumab","volume":"246","author":"Bakri SJ","year":"2008","unstructured":"Bakri SJ, Larson TA, Edwards AO. Intraocular inflammation following intravitreal injection of bevacizumab. Graefes Arch Clin Exp Ophthalmol. 2008, 246:779-81. 10.1007\/s00417-007-0754-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002351","article-title":"Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab","volume":"39","author":"Bavinger JC","year":"2019","unstructured":"Bavinger JC, Yu Y, VanderBeek BL. Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab. Retina. 2019, 39:2004-11. 10.1097\/IAE.0000000000002351","journal-title":"Retina"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-025-04093-w","article-title":"Endophthalmitis following intravitreal injections at a tertiary center: real-life data on incidence, risk factors, management strategies, and visual outcomes","volume":"25","author":"Comcali S","year":"2025","unstructured":"Comcali S, Tasci YY, Onen M, et al.. Endophthalmitis following intravitreal injections at a tertiary center: real-life data on incidence, risk factors, management strategies, and visual outcomes. BMC Ophthalmol. 2025, 25:278. 10.1186\/s12886-025-04093-w","journal-title":"BMC Ophthalmol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.099598","article-title":"The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide","volume":"90","author":"Fung AE","year":"2006","unstructured":"Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol. 2006, 90:1344-9. 10.1136\/bjo.2006.099598","journal-title":"Br J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.4103\/0301-4738.98712","article-title":"Managing bevacizumab-induced intraocular inflammation","volume":"60","author":"Sinha S","year":"2012","unstructured":"Sinha S, Vashisht N, Venkatesh P, Garg SP. Managing bevacizumab-induced intraocular inflammation. Indian J Ophthalmol. 2012, 60:311-3. 10.4103\/0301-4738.98712","journal-title":"Indian J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.4103\/ijo.IJO_804_17","article-title":"Recommendations for an expert team investigating a case of cluster endophthalmitis","volume":"66","author":"Desai SR","year":"2018","unstructured":"Desai SR, Bhagat PR, Parmar D. Recommendations for an expert team investigating a case of cluster endophthalmitis. Indian J Ophthalmol. 2018, 66:1074-8. 10.4103\/ijo.IJO_804_17","journal-title":"Indian J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/928123","article-title":"Sterile endophthalmitis after intravitreal injections","volume":"2012","author":"Marticorena J","year":"2012","unstructured":"Marticorena J, Romano V, G\u00f3mez-Ulla F. Sterile endophthalmitis after intravitreal injections. Mediators Inflamm. 2012, 2012:928123. 10.1155\/2012\/928123","journal-title":"Mediators Inflamm"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00307-7","article-title":"Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review","volume":"7","author":"Anderson WJ","year":"2021","unstructured":"Anderson WJ, da Cruz NF, Lima LH, Emerson GG, Rodrigues EB, Melo GB. Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review. Int J Retina Vitreous. 2021, 7:37. 10.1186\/s40942-021-00307-7","journal-title":"Int J Retina Vitreous"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S169143","article-title":"Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis","volume":"12","author":"Kiss S","year":"2018","unstructured":"Kiss S, Dugel PU, Khanani AM, Broder MS, Chang E, Sun GH, Turpcu A. Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis. Clin Ophthalmol. 2018, 12:1625-35. 10.2147\/OPTH.S169143","journal-title":"Clin Ophthalmol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.5693\/djo.01.2016.03.001","article-title":"A cluster of presumed, noninfectious endophthalmitis after intravitreal injection of bevacizumab: long-term follow-up","volume":"22","author":"Ricci F","year":"2016","unstructured":"Ricci F, Calabrese A, De Felici C, Missiroli F, Pileri M, Regine F. A cluster of presumed, noninfectious endophthalmitis after intravitreal injection of bevacizumab: long-term follow-up. Digit J Ophthalmol. 2016, 22:41-5. 10.5693\/djo.01.2016.03.001","journal-title":"Digit J Ophthalmol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-005-0082-8","article-title":"Ten years after... are findings of the Endophthalmitis Vitrectomy Study still relevant today?","volume":"243","author":"Kuhn F","year":"2005","unstructured":"Kuhn F, Gini G. Ten years after... are findings of the Endophthalmitis Vitrectomy Study still relevant today?. Graefes Arch Clin Exp Ophthalmol. 2005, 243:1197-9. 10.1007\/s00417-005-0082-8","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1995.01100120009001","article-title":"Results of the Endophthalmitis Vitrectomy Study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis","volume":"113","year":"1995","unstructured":"Results of the Endophthalmitis Vitrectomy Study. a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis. Arch Ophthalmol. 1995, 113:1479-96. 10.1001\/archopht.1995.01100120009001","journal-title":"Arch Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2017.11.021","article-title":"Endophthalmitis: then and now","volume":"187","author":"Relhan N","year":"2018","unstructured":"Relhan N, Forster RK, Flynn HW Jr. Endophthalmitis: then and now. Am J Ophthalmol. 2018, 187:xx-xxvii. 10.1016\/j.ajo.2017.11.021","journal-title":"Am J Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/IIO.0000000000000580","article-title":"Sterile intraocular inflammation following intravitreal injections: pathogenesis, clinical features, and management","volume":"65","author":"Bagheri S","year":"2025","unstructured":"Bagheri S, Ntentakis DP, Emfietzoglou M, et al.. Sterile intraocular inflammation following intravitreal injections: pathogenesis, clinical features, and management. Int Ophthalmol Clin. 2025, 65:63-70. 10.1097\/IIO.0000000000000580","journal-title":"Int Ophthalmol Clin"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-021-01886-3","article-title":"Intravitreal injections as a leading cause of acute postoperative endophthalmitis\u2014a regional survey in England","volume":"37","author":"Ong AY","year":"2023","unstructured":"Ong AY, Rigaudy A, Toufeeq S, Robins J, Shalchi Z, Bindra MS, Charbel Issa P. Intravitreal injections as a leading cause of acute postoperative endophthalmitis\u2014a regional survey in England. Eye (Lond). 2023, 37:163-9. 10.1038\/s41433-021-01886-3","journal-title":"Eye (Lond)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2021097","article-title":"Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology","volume":"43","author":"Mun Y","year":"2021","unstructured":"Mun Y, You SC, Lee DY, et al.. Real-world incidence of endopthalmitis after intravitreal anti-VEGF injections in Korea: findings from the Common Data Model in ophthalmology. Epidemiol Health. 2021, 43:e2021097. 10.4178\/epih.e2021097","journal-title":"Epidemiol Health"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.3591","article-title":"Evaluation of compounded bevacizumab prepared for intravitreal injection","volume":"133","author":"Yannuzzi NA","year":"2015","unstructured":"Yannuzzi NA, Klufas MA, Quach L, et al.. Evaluation of compounded bevacizumab prepared for intravitreal injection. JAMA Ophthalmol. 2015, 133:32-9. 10.1001\/jamaophthalmol.2014.3591","journal-title":"JAMA Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/943409","article-title":"Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy","volume":"2013","author":"Agrawal S","year":"2013","unstructured":"Agrawal S, Joshi M, Christoforidis JB. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy. Mediators Inflamm. 2013, 2013:943409. 10.1155\/2013\/943409","journal-title":"Mediators Inflamm"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-024-03134-5","article-title":"Clinical features, management, and outcomes of patients with sterile endophthalmitis associated with intravitreal bevacizumab injection: retrospective case series","volume":"44","author":"Kivrak U","year":"2024","unstructured":"Kivrak U, Arsan AK, Ak\u00e7ay G, Bulut MN, Kanar HS, Hac\u0131saliho\u011flu AO, \u015eim\u015fek \u015e. Clinical features, management, and outcomes of patients with sterile endophthalmitis associated with intravitreal bevacizumab injection: retrospective case series. Int Ophthalmol. 2024, 44:216. 10.1007\/s10792-024-03134-5","journal-title":"Int Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S66230","article-title":"Acute sterile endophthalmitis following intravitreal bevacizumab: case series","volume":"8","author":"Orozco-Hern\u00e1ndez A","year":"2014","unstructured":"Orozco-Hern\u00e1ndez A, Ortega-Larrocea X, S\u00e1nchez-Berm\u00fadez G, Garc\u00eda-Aguirre G, Cant\u00f3n VM, Velez-Montoya R. Acute sterile endophthalmitis following intravitreal bevacizumab: case series. Clin Ophthalmol. 2014, 8:1793-9. 10.2147\/OPTH.S66230","journal-title":"Clin Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2007.136069","article-title":"Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide","volume":"92","author":"Jonisch J","year":"2008","unstructured":"Jonisch J, Lai JC, Deramo VA, Flug AJ, Fastenberg DM. Increased incidence of sterile endophthalmitis following intravitreal preserved triamcinolone acetonide. Br J Ophthalmol. 2008, 92:1051-4. 10.1136\/bjo.2007.136069","journal-title":"Br J Ophthalmol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S207978","article-title":"Issues with intravitreal administration of anti-VEGF drugs","volume":"14","author":"Schargus M","year":"2020","unstructured":"Schargus M, Frings A. Issues with intravitreal administration of anti-VEGF drugs. Clin Ophthalmol. 2020, 14:897-904. 10.2147\/OPTH.S207978","journal-title":"Clin Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000000399","article-title":"Intravitreal injection technique and monitoring: updated guidelines of an expert panel","volume":"34 Suppl 12","author":"Avery RL","year":"2014","unstructured":"Avery RL, Bakri SJ, Blumenkranz MS, et al.. Intravitreal injection technique and monitoring: updated guidelines of an expert panel. Retina. 2014, 34 Suppl 12:S1-S18. 10.1097\/IAE.0000000000000399","journal-title":"Retina"},{"key":"ref26","article-title":"Section 2.6.14: bacterial endotoxins","year":"2023","unstructured":"Section 2.6.14. bacterial endotoxins. European Pharmacopoeia, 11th Edition. Council of Europe, Strasbourg; 2023."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2022.2113101","article-title":"Recent advances and ongoing challenges in the diagnosis of culture negative endophthalmitis","volume":"38","author":"Naik P","year":"2023","unstructured":"Naik P, Gandhi J, Joseph J. Recent advances and ongoing challenges in the diagnosis of culture negative endophthalmitis. Semin Ophthalmol. 2023, 38:92-8. 10.1080\/08820538.2022.2113101","journal-title":"Semin Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12118","article-title":"Endophthalmitis","volume":"19","author":"Durand ML","year":"2013","unstructured":"Durand ML. Endophthalmitis. Clin Microbiol Infect. 2013, 19:227-34. 10.1111\/1469-0691.12118","journal-title":"Clin Microbiol Infect"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2018-312877","article-title":"Utility of broad-range 16S rRNA PCR assay versus conventional methods for laboratory diagnosis of bacterial endophthalmitis in a tertiary care hospital","volume":"103","author":"Mishra D","year":"2019","unstructured":"Mishra D, Satpathy G, Chawla R, Venkatesh P, Ahmed NH, Panda SK. Utility of broad-range 16S rRNA PCR assay versus conventional methods for laboratory diagnosis of bacterial endophthalmitis in a tertiary care hospital. Br J Ophthalmol. 2019, 103:152-6. 10.1136\/bjophthalmol-2018-312877","journal-title":"Br J Ophthalmol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2020.03.008","article-title":"Prognostic utility of whole-genome sequencing and polymerase chain reaction tests of ocular fluids in postprocedural endophthalmitis","volume":"217","author":"Lee CS","year":"2020","unstructured":"Lee CS, Hong B, Kasi SK, et al.. Prognostic utility of whole-genome sequencing and polymerase chain reaction tests of ocular fluids in postprocedural endophthalmitis. Am J Ophthalmol. 2020, 217:325-34. 10.1016\/j.ajo.2020.03.008","journal-title":"Am J Ophthalmol"},{"key":"ref31","article-title":"ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery: Data, Dilemmas and Conclusions","author":"Barry P","year":"2013","unstructured":"Barry P, Cordov\u00e9s L, Gardner S. ESCRS Guidelines for Prevention and Treatment of Endophthalmitis Following Cataract Surgery: Data, Dilemmas and Conclusions. European Society of Cataract and Refractive Surgeons, 2013."},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2024.2749","article-title":"Endophthalmitis rates and types of treatments after intraocular procedures","volume":"142","author":"VanderBeek BL","year":"2024","unstructured":"VanderBeek BL, Chen Y, Tomaiuolo M, et al.. Endophthalmitis rates and types of treatments after intraocular procedures. JAMA Ophthalmol. 2024, 142:827-34. 10.1001\/jamaophthalmol.2024.2749","journal-title":"JAMA Ophthalmol"},{"key":"ref33","unstructured":"Bevacizumab. recommendations for ophthalmic use. (2020). http:\/\/www.ema.europa.eu."},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13061269","article-title":"Cytometric evaluation of cytokine factors in serum and vitreous from endophthalmitis patients: correlated elevation in neutrophil markers","volume":"13","author":"Carroll C","year":"2025","unstructured":"Carroll C, Joseph D, Allen PJ, Hewitt AW, Rutar M, Dawkins RC. Cytometric evaluation of cytokine factors in serum and vitreous from endophthalmitis patients: correlated elevation in neutrophil markers. Biomedicines. 2025, 13:1269. 10.3390\/biomedicines13061269","journal-title":"Biomedicines"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1177\/24741264241275246","article-title":"Unified approach to treating exogenous endophthalmitis with immediate vitrectomy","volume":"8","author":"Loh GK","year":"2024","unstructured":"Loh GK, Mishra AV, Seamone M, Tennant M. Unified approach to treating exogenous endophthalmitis with immediate vitrectomy. J Vitreoretin Dis. 2024, 8:694-8. 10.1177\/24741264241275246","journal-title":"J Vitreoretin Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/409043-complete-and-early-vitrectomy-for-sterile-endophthalmitis-after-bevacizumab-a-case-series","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T07:22:36Z","timestamp":1759821756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/409043-complete-and-early-vitrectomy-for-sterile-endophthalmitis-after-bevacizumab-a-case-series"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.93996","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,7]]}}}